Hepatitis B surface Ag
Description:
Qualitative chemiluminescent immunoassay (CLIA) for the detection of Hepatitis B surface antigen in serum. This test is used to diagnose current infection with Hepatitis B virus. Confirmed positive patients undergo further testing for Hepatitis B e antigen and e antibody and a second sample is required for this. DO NOT test within 2 weeks subsequent to a Hepatitis B vaccination dose as this interferes with assay interpretation. This assay is available as a screening test Mon to Sun.
This test is not UKAS accredited
This test is not UKAS accredited
Clinical details:
Hepatitis B infection affects an estimated 350 million people and accounts for 1 million deaths worldwide. Infection, particularly if acquired in infancy can remain lifelong and lead to cirrhosis and hepatocellular carcinoma. Hepatitis B can be transmitted from mother to child during childbirth (commonest route in high prevalence areas), through sexual contact or through injecting drug use. The risk of having chronic infection mostly reflects the prevalence in a persons country of birth. Ante-natal screening and vaccination of at risk infants has been incredibly effective at reducing transmission of hepatitis B. Proper clinical monitoring and treatment where appropriate can significantly reduce the likelihood of complications of Hepatitis B.
Reference range:
Not Applicable
Units:
Qualitative Test - Detected/Not Detected
Department:
Location:
Sample type and Volume required:
2.5 - 5 ml Yellow Top Serum Separation Tube (SST) Clotted Blood (for Serum).
Turnaround time:
3 working days
Storage and transport:
Place labelled sample in a sealed sample bag and send to Central Specimen Reception (CSR). To prevent sample haemolysis please store samples in refrigerator if a delay in sending samples to CSR is unavoidable.
Contacts:
For clinical advice or interpretation of results, please contact the laboratory in the first instance.
Laboratory:
Last updated: 18/12/2024
